Seres Therapeutics (MCRB) Assets (2014 - 2026)

Seres Therapeutics has disclosed Assets across 13 years of filings, most recently posting $101.6 million for Q2 2026.

• In Q2 2026, Assets fell 29.35% year-over-year to $101.6 million; the TTM figure through Jun 2026 stood at $101.6 million (down 29.35% YoY), while the FY2025 annual figure was $138.2 million, down 1.16% from the prior year.
• Assets came in at $101.6 million for Q2 2026 at Seres Therapeutics, down from $117.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $406.4 million in Q2 2023 to a low of $101.6 million in Q2 2026.
• Average Assets over 5 years is $247.1 million, with a median of $271.7 million recorded in 2022.
• Year-over-year, Assets soared 48.75% in 2023 and tumbled 61.01% in 2024.
• Over 5 years, Assets stood at $348.8 million in 2022, then increased by 2.81% to $358.6 million in 2023, then sank by 61.01% to $139.8 million in 2024, then decreased by 1.16% to $138.2 million in 2025, then dropped by 26.49% to $101.6 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $101.6 million in Q2 2026, $117.6 million in Q1 2026, and $138.2 million in Q4 2025.